Nevirapine resistance after single dose prophylaxis

AIDS Reviews

Volumn 4, Issue 2, 2002, Pages 59-63

  Eshleman, Susan H ^a   Jackson, J Brooks ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

HIV 1; Mother to child transmission; Nevirapine; Prophylaxis; Resistance

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DELAVIRDINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; BIRTH; CLINICAL TRIAL; CROSS RESISTANCE; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG POTENCY; FEMALE; HEALTH CARE PLANNING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LABOR; LYMPHOCYTE COUNT; NONHUMAN; RESOURCE MANAGEMENT; REVIEW; VERTICAL TRANSMISSION; VIRUS DETECTION; VIRUS LOAD; VIRUS MUTATION; CD4 LYMPHOCYTE COUNT; DISEASE TRANSMISSION; DRUG EFFECT; GENETICS; MUTATION; PREGNANCY; PREGNANCY COMPLICATION; UGANDA;

CD4 LYMPHOCYTE COUNT; DISEASE TRANSMISSION, VERTICAL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMAN; INFANT; MUTATION; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; REVERSE TRANSCRIPTASE INHIBITORS; SUPPORT, U.S. GOV'T, P.H.S.; UGANDA; VIRAL LOAD; HUMANS;

EID: 0035988448     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Pharmacokinetics of nevirapine in HIV type 1 - Infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team
2. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006)
3. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-infant transmission of HIV-1 in Kampala, Uganda: HIVNET-012 randomised trial
4. The one year safety and efficacy data of the HIVNET 012 trial
5. Public Health Service Task Force recommendations for the use of anti-retroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States
6. Nevirapine-resistant HIV: Kinetics of replication and estimated prevalence in untreated patients
7. The impact of HIV-1 subtype on drug resistance
8. A molecular epidemiologic survey of HIV in Uganda. HIV variant working group
9. Predominance of HIV-1 subtype A and D infections in Uganda
10. Novel deletion of HIV type 1 reverse transcriptase residue 69 conferring selective high-level resistance to nevirapine
11. Reduced susceptibility of HIV-1 from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acids sites
12. Analysis of HIV-1 protease and reverse transcriptase in antiretroviral drug naïve Ugandan adults
13. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012)
14. Natural variation in susceptibility to non-nucleoside reverse transcriptase inhibitors (NNRTI) pre-dates drug availability
15. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B HIV type 1 strains: Evidence of many minor drug resistance mutations in treatment-naïve patients
16. Identification of the K103N mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission
17. Comparison of nevirapine resistance mutations in women vs infants receiving single dose NVP prophylaxis to prevent HIV-1 vertical transmission (HIVNET 012)
18. A novel phenotypic drug susceptibility assay for HIV type 1
19. Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: Clinical and genotypic predictors of virologic response
20. Cross-resistance among non-nucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure
21. Impact of HIV-1 subtype on women receiving single dose NVP prophylaxis to prevent HIV-1 vertical transmission (HIVNET 012)
22. Comparison of mother to child transmission and genotypic resistance in HIV-1 subtypes A, C and D after single dose nevirapine in Africa
23. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management